Small but significant - the role of microRNAs in the formation, detection and treatment of cancer based on gastric cancer
Keywords:
microRNA, biomarker, carcinogenesis, gastric cancerAbstract
In the era of intensive development of lifestyle diseases such as stomach cancer, it is crucial to design markers that enable their early detection, allow rapid introduction of treatment and prevent the increase in the number of deceases. Potential possibility is microRNAs, short RNA molecules which modulate the activity of specific fragments of RNA and play an important role in many physiological and pathological processes. Affecting cell proliferation, cell cycle and apoptosis of cancer cells also play a significant role in neoplasia. Detectable levels of derogation from the regular level associated with each of the stages of tumor development may make them effective and non-invasive biomarkers, allowing not only for early detection and identification of cancer’s type, but also on their prediction. Further understanding of their functions and properties can result in the discovery of effective methods of cancer treatment.
Downloads
References
Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochimica et biophysica acta. 2010;1806(2):200-7.
Anderson MW, Reynolds SH, You M, Maronpot RM. Role of proto-oncogene activation in carcinogenesis. Environmental health perspectives. 1992;98:13-24.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54.
Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nature genetics. 2005;37(7):766-70.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(30):10513-8.
Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. International journal of cancer Journal international du cancer. 2011;128(10):2274-83.
Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27(12):1788-93.
Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Current opinion in cell biology. 2004;16(3):223-9.
Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development. 2005;132(21):4645-52.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635-47.
Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Molecular and cellular biology. 2009;29(19):5290-305.
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010;51(3):836-45.
Jiang P, Rao EY, Meng N, Zhao Y, Wang JJ. MicroRNA-17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol. 2010;5:100.
Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatric research. 2007;61(5 Pt 2):24R-9R.
Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature. 2005;435(7043):745-6.
Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovascular research. 2012;93(4):555-62.
Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature cell biology. 2008;10(12):1470-6.
Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Advances in experimental medicine and biology. 2007;604:17-46.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer research. 2005;65(16):7065-70.
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. International journal of cancer Journal international du cancer. 2007;120(5):1046-54.
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer research. 2007;67(18):8699-707.
Gandellini P, Folini M, Zaffaroni N. Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discovery medicine. 2010;9(46):212-8.
Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S, et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One. 2011;6(9):e24922.
Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. British journal of cancer. 2012;106(3):553-61.
Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, et al. Prognostic Values of microRNAs in Colorectal Cancer. Biomarker insights. 2006;2:113-21.
Varnholt H. The role of microRNAs in primary liver cancer. Annals of hepatology. 2008;7(2):104-13.
Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. International journal of oncology. 2009;35(1):109-14.
Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocrine pathology. 2009;20(2):85-91.
Grzebieniak Z., Kurkiewicz E., Rudno-Rudzinska J., Kielan W. Zaawansowany nowotwór żołądka leczony chirurgicznie z istotnymi powikłaniami. http://www.przypadkimedyczne.pl/czasopismo/papers/1-2012-full.pdf(10.05.2012).
Halvorsen RA, Jr., Yee J, McCormick VD. Diagnosis and staging of gastric cancer. Seminars in oncology. 1996;23(3):325-35.
Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, et al. microRNA expression profile in undifferentiated gastric cancer. International journal of oncology. 2009;34(2):537-42.
Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, et al. Identification of Serum MicroRNAs as Novel Non-Invasive Biomarkers for Early Detection of Gastric Cancer. PLoS One. 2012;7(3):e33608.
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. The lancet oncology. 2010;11(2):136-46.
Liao YL, Hu LY, Tsai KW, Wu CW, Chan WC, Li SC, et al. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. Carcinogenesis. 2012;33(4):760-9.
Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010;31(12):2066-73.
Czasopismo
Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer cell. 2008;13(3):272-86.
Tsai KW, Kao HW, Chen HC, Chen SJ, Lin WC. Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics : official journal of the DNA Methylation Society. 2009;4(8):587-92.
Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, et al. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics : official journal of the DNA Methylation Society. 2011;6(10):1189-97.
Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncology reports. 2012;27(6):1759-64.
Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer letters. 2010;298(1):50-63.
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, et al. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Molecules and cells. 2009;28(6):521-7.
Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2011.
Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Digestive diseases and sciences. 2011;56(7):2009-16.
Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC cancer. 2008;8:266.
Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(8):2334-40.
Li C, Nie H, Wang M, Su L, Li J, Yu B, et al. MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer letters. 2012;320(2):189-97.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
